Table 1.

Patient characteristics and indications for ¹⁸F-FDG PET/CT scans

Pt	18F-FDG PET/CT indication	Prostate mpMRI before or after PET?	Prostate mpMRI indication	Worst Gleason	Age (yr)	PSA (ng/mL)	Prostate volume (mL)	PSAD	SUVmax, prostate
1	Metastatic RCC	before	Abnormal DRE	Benign	53	2.65	45	0.06	3.33
2	Pheochromocytoma	after	Elevated PSA	Benign	49	4.48	35	0.13	5.90
3	RCC	before	Elevated PSA	Benign	72	4.43	152	0.03	4.70
4	Lung nodule	before	Elevated PSA	3+3	56	13.10	75	0.17	4.10
5	Mantle cell lymphoma	after	Elevated PSA and prior negative TRUS biopsy	3+4	70	9.64	36	0.27	4.61
6	Metastatic RCC	before	Elevated PSA	3+4	75	7.50	54	0.14	4.96
7	MGUS	before	Elevated PSA	3+4	73	8.72	40	0.22	3.98
8	HCC	before	Elevated PSA	3+4	55	8.60	32	0.27	7.24
9	Large cell lung cancer	before	Elevated PSA	4+4	59	8.58	26	0.33	2.99
10	Lung adenocarcinoma	before	Elevated PSA and prior negative TRUS biopsy	4+4	67	14.10	32	0.44	6.25
11	Metastatic papillary thyroid cancer	after	Incidental 18F-FDG prostate uptake	4+4	61	2.64	41	0.06	25.35
12	Follicular lymphoma	after	Elevated PSA	4+4	70	8.28	38	0.22	5.63
13	Pheochromocytoma	after	Elevated PSA	4+4	72	14.95	28	0.53	7.00
14	Metastatic workup	before	Elevated PSA and two prior negative TRUS biopsies	4+5	77	27.10	57	0.48	16.85
15	Metastatic thymoma	after	Incidental 18F-FDG prostate uptake	4+5	66	8.53	33	0.26	6.64
16	Metastatic workup	before	Elevated PSA	5+4	72	6.90	45	0.15	19.31
17	Metastatic workup	before	Elevated PSA	5+5	51	39.64	60	0.66	13.91
				Mean	65	11.17	49	0.26	8.40
				Min	49	2.64	26	0.03	2.99
				Max	77	39.64	152	0.66	25.35

Pt = patient; yr = years; PSAD = PSA density; RCC = renal cell carcinoma, MGUS = monoclonal gammopathy of undetermined significance, HCC = hepatocellular carcinoma; DRE = digital rectal exam; TRUS = transrectal ultrasound